Author

Yonina Keschner

ORCID 0009-0004-5703-2414Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Huanying Gary Ge· 2 shared John R. LydeardiD· 2 shared Julia Etchin· 2 shared Tirtha ChakrabortyiD· 2 shared Abhinav DhalliD· 1 shared Alyssa Pyclik· 1 shared Amanda L. Halfond· 1 shared Hannah MageriD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetics

Huanying Gary Ge

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GeneticsbioRxivPreprintDec 17, 2025

A Human Genetics Framework for De-risking Gene Editing Targets for Hematopoietic Cell and Gene Therapy

Abhinav Dhall, Alyssa Pyclik, Matthew H. Ung…·John R. Lydeard

The paper develops a proteogenomic framework to identify dispensable genes for safer gene editing in hematopoietic therapies, identifying 237 candidates including LY75.

DOI 10.64898/2025.12.15.694499

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 21, 2025

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML Therapy

Yonina Keschner, Julia Etchin, Mariana Camoesas Silva…·John R. Lydeard

This study evaluates ADGRE2 as an AML target, showing efficient gene editing in HSPCs to protect against myelotoxicity and developing ADGRE2-specific CAR T cells for therapy.

DOI 10.1101/2025.08.21.671614

humangenetic perturbation / CRISPR

𝕏 PostBluesky